Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
McKesson
Johnson and Johnson
Baxter
Express Scripts

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for AP1903

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug AP1903?

AP1903 is an investigational drug.

There have been 21 clinical trials for AP1903. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2018.

The most common disease conditions in clinical trials are Myelodysplastic Syndromes, Preleukemia, and Precursor Cell Lymphoblastic Leukemia-Lymphoma. The leading clinical trial sponsors are Bellicum Pharmaceuticals, National Cancer Institute (NCI), and M.D. Anderson Cancer Center.

There are two US patents protecting this investigational drug and twenty-one international patents.

Recent Clinical Trials for AP1903
TitleSponsorPhase
T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple MyelomaNational Cancer Institute (NCI)Phase 1
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell TransplantBellicum PharmaceuticalsPhase 1
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell TransplantNational Cancer Institute (NCI)Phase 1

See all AP1903 clinical trials

Clinical Trial Summary for AP1903

Top disease conditions for AP1903
Top clinical trial sponsors for AP1903

See all AP1903 clinical trials

US Patents for AP1903

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AP1903   Start Trial Synthetic multimerizing agents ARIAD Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
AP1903   Start Trial Synthetic multimerizing agents ARIAD Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AP1903

Drugname Country Document Number Estimated Expiration Related US Patent
AP1903 Austria 299145 2014-08-18   Start Trial
AP1903 Austria 465149 2014-08-18   Start Trial
AP1903 Australia 1980997 2014-08-18   Start Trial
AP1903 Australia 2192797 2014-08-18   Start Trial
AP1903 Australia 3367995 2014-08-18   Start Trial
AP1903 Australia 731826 2014-08-18   Start Trial
AP1903 Canada 2197793 2014-08-18   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Baxter
Harvard Business School
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.